Nowture Enters the Capital of the Spanish Biotech Company Libera Bio

Nowture is once again betting on biotech. The biotech ecosystem that offers a comprehensive model of support services for companies in the sector has entered the capital of Libera Bio, a company specialized in applying nanotechnology in the development of oncological therapies to gain efficacy and eliminate the toxicity of current treatments.

Nowture has participated in a round in which it is the lead investor and reserves the right to lead the following capital increases up to an amount of six million euros, explains the group.

Libera Bio’s patented technology, MPN Technology, aims to develop a new paradigm in the treatment of cancer by making it possible to treat cellular targets that have so far been inaccessible pharmacologically.

These cancer targets are hidden inside tumor cells and to date are almost impossible to access with current immunotherapy treatments. Libera Bio’s technology, should it eventually reach the market, would allow access to the targets inside tumor cells, without affecting healthy cells.

Find more details about Nowenture and its recent investment in the biotech company Libera Bio with the Born2Invest mobile app. Our companion app brings you the most important business headlines so you can stay informed.

Nowture has financial instruments for a cumulative value of three million euros

Libera Bio is a spin-off from the laboratory of scientist María José Alonso at the University of Santiago de Compostela (Galicia). It is developing a series of patents around the Multifunctional Polymeric Nanocapsules Technology (NPM).

These nanocapsules, with a lipid core and multiple layers around it, make it possible to transport small and large molecules (biologics such as monoclonal antibodies or siRNA), target them to cancer cells and lymph nodes (which often have metastatic cells) and even deliver their cargo inside the tumor cells, thanks to a receptor attached to the polymeric shell of the nanocapsules.

Preclinical in vivo studies have already shown positive results (tumor necrosis, apoptosis of cancer cells), in animal models of various types of tumors (pancreas, colorectal, or lung).

“We are excited about the arrival of Libera Bio to our ecosystem as it could represent a breakthrough in cancer treatment in the future, achieving effective precision medicine drugs with fewer side effects,” explains Mario Grande, CEO and founder of Nowture.

Nowture is a comprehensive ecosystem that invests in and offers a global model of support services for transformative companies in the life sciences sector. The company has financial instruments with a cumulative value of three million euros, with a portfolio of eight investees, including the biopharmaceutical companies Laminar Pharma and Neurofix, currently in Pre-Market Environment (EpM) of Bolsas y Mercados Españoles, for its next listing on BME Growth.

The Spanish company is also working on the launch of a fund of around 50 million euros. This is an investment fund resulting from the alliance between Nowture and the alternative financing platform Fellow Funders, which both companies expect to be operational in 2022.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.